Skip to search formSkip to main contentSkip to account menu

lansoprazole

Known as: 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole, Lansoprazole [Chemical/Ingredient], Lansoprazoles 
A substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. Lansoprazole prodrug is converted to an active… 
National Institutes of Health

Related topics

Related topics

39 relations

Narrower (18)

AG 1749AgoptonLansolLansoprazole Sodium

Broader (2)

Anti-Ulcer AgentProton Pump Inhibitors
CYP2C19 protein, humanDrug AllergyDuodenal UlcerEsophagitis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
DESIGN AND DEVELOPMENT OF CHRONOPHARMACEUTICAL DRUG DELIVERY OF LANSOPRAZOLE
The aim of the present investigation is to develop a pulsatile drug delivery system basedon an insoluble capsule body filled with… 
2012
2012
A validated, specific, stability-indicating HPLC method for determination of lansoprazole enteric capsules and related impurities
An isocratic reversed phase high performance liquid chromatographic method with UV detection was developed for the analysis of… 
2011
2011
Lansoprazole solid dispersion using a novel amphiphillic polymer SoluplusÃÂ
The aim of the present study was to prepare solid dispersion (SD) of Lansoprazole (LSP) to improve its saturation solubility and… 
2010
2010
Anti-Ro and anti-La antibody positive subacute cutaneous lupus erythematosus (SCLE) induced by lansoprazole.
Auteur(s) : Collette Mccourt1, Jennifer Somerville2, Kevin McKenna1 1Belfast City Hospital, Dermatology Department, Belfast City… 
2003
2003
Comparison of transnasaly placed wireless pH capsule (BRAVO®) versus traditional 24-hour esophageal pH monitoring-a randomized trial
Purpose: The wireless pH capsule (BRAVO®) can be placed either during endoscopy or transnasaly. However, for open-access motility… 
2002
2002
HPLC Analysis for Omeprazole and Lansoprazole in Blood Plasma
Omeprazole and lansoprazole are new-generation antiulcer preparations, representing “proton pump” inhibitors [1]. The former is a… 
1998
1998
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment…
BACKGROUND The Maastricht Consensus Report advises that, in Helicobacter pylori-positive patients after surgery for peptic ulcer… 
1997
1997
Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
OBJECTIVE: To compare the effects of long-term lansoprazole and omeprazole treatment (6 months) on serum gastrin levels. PATIENTS… 
1995
1995
Efficacy of Lansoprazole in Eradication of Helicobacter pylori
Fifty-eight Helicobacter pylori-positive ulcer patients received omeprazole 20 mg (n = 15), or lansoprazole 30 mg (n = 23… 
1995
1995
Clinical Study on the Pathophysiology and Treatment of PPI‐Resistant Ulcers
We studied the gastric acidity, gastric emptying, and proton pump inhibitor (PPI) plasma levels in 10 patients with PPI-resistant…